• Profile
Close

A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis

Journal of Clinical Endocrinology & Metabolism Sep 12, 2018

Lewiecki EM, et al. – This phase 3, randomized, double-blind, placebo-controlled BRIDGE study evaluated the efficacy and safety of romosozumab in men aged 55 to 90 years with osteoporosis for 12 months. Compared with those in the placebo group, 12-month romosozumab treatment increased spine and hip bone mineral density (BMD), and was well tolerated in men with osteoporosis. Results suggested that romosozumab may be a new and promising bone-forming treatment for men with osteoporosis.

Methods

  • This investigation was conducted at 31 centers in Europe, Latin America, Japan, and North America.
  • Study participants were men aged 55 to 90 years with a baseline BMD T-score at the lumbar spine (LS), total hip (TH), or femoral neck of ≤-2.5 or ≤-1.5 with a history of a fragility nonvertebral or vertebral fracture.
  • Participants were randomized 2:1 to receive romosozumab 210 mg subcutaneously monthly or placebo for 12 months.
  • Percentage change from baseline in LS BMD at month 12 was the primary efficacy endpoint.

Results

  • At month 12, the mean percentage change from baseline in the LS and TH BMD was significantly greater for the romosozumab group vs the placebo group (LS, 12.1% vs 1.2%; TH, 2.5% vs -0.5%; P < 0.001) in 245 subjects (163 romosozumab, 82 placebo).
  • Findings showed that adverse events (AEs) and serious AEs were balanced between the two groups, with a numerical imbalance in the positively adjudicated cardiovascular serious AEs [romosozumab, 8 (4.9%) vs placebo, 2 (2.5%)].
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay